Biological evaluation and molecular docking studies of AA3052, a compound containing a μ-selective opioid peptide agonist DALDA and D-Phe-Phe-D-Phe-Leu-Leu-NH2, a substance P analogue

Agnieszka Kowalczyk, Patrycja Kleczkowska, Monika Rękawek, Kamila Kulik, Anna Lesniak, A. Erdei, Attila Borics, Charlotte Martin, Karolina Pawlik, Andrzej W. Lipkowski, S. Benyhe, Helena Makulska-Nowak, Steven Ballet, Magdalena Bujalska-Zadrozny

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The design of novel drugs for pain relief with improved analgesic properties and diminished side effect induction profile still remains a challenging pursuit. Tolerance is one of the most burdensome phenomena that may hamper ongoing opioid therapy, especially in chronic pain patients. Therefore, a promising strategy of hybridizing two pharmacophores that target distinct binding sites involved in pain modulation and transmission was established. Previous studies have led to the development of opioid agonist/NK1 agonist hybrids that produce sufficient analgesia and also suppress opioid-induced tolerance development. In our present investigation we assessed the antinociceptive potency of a new AA3052 chimera comprised of a potent MOR selective dermorphin derivative (DALDA) and an NK1 agonist, a stabilized substance P analogue. We have shown that AA3052 significantly prolonged responses to both mechanical and noxious thermal stimuli in rats after intracerebroventricular administration. Additionally, AA3052 did not trigger the development of tolerance in a 6-day daily injection paradigm nor did it produce any sedative effects, as assessed in the rotarod performance test. However, the antinociceptive effect of AA3052 was independent of opioid receptor stimulation by the DALDA pharmacophore as shown in the agonist-stimulated G-protein assay. Altogether the current results confirm the antinociceptive effectiveness of a novel opioid/SP hybrid agonist, AA3052, and more importantly its ability to inhibit the development of tolerance.

Original languageEnglish
Pages (from-to)11-20
Number of pages10
JournalEuropean Journal of Pharmaceutical Sciences
Volume93
DOIs
Publication statusPublished - Oct 10 2016

Fingerprint

phenylalanylphenylalanine
Opioid Peptides
Substance P
Opioid Analgesics
Rotarod Performance Test
Pain
Aptitude
Drug Design
Opioid Receptors
Hypnotics and Sedatives
GTP-Binding Proteins
Chronic Pain
Analgesia
Analgesics
Hot Temperature
Binding Sites
Injections
tyrosyl-arginyl-phenylalanyl-lysinamide

Keywords

  • Analgesia
  • Anticancer activity
  • DALDA
  • Hybrid peptide
  • Substance P
  • Tolerance

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Biological evaluation and molecular docking studies of AA3052, a compound containing a μ-selective opioid peptide agonist DALDA and D-Phe-Phe-D-Phe-Leu-Leu-NH2, a substance P analogue. / Kowalczyk, Agnieszka; Kleczkowska, Patrycja; Rękawek, Monika; Kulik, Kamila; Lesniak, Anna; Erdei, A.; Borics, Attila; Martin, Charlotte; Pawlik, Karolina; Lipkowski, Andrzej W.; Benyhe, S.; Makulska-Nowak, Helena; Ballet, Steven; Bujalska-Zadrozny, Magdalena.

In: European Journal of Pharmaceutical Sciences, Vol. 93, 10.10.2016, p. 11-20.

Research output: Contribution to journalArticle

Kowalczyk, A, Kleczkowska, P, Rękawek, M, Kulik, K, Lesniak, A, Erdei, A, Borics, A, Martin, C, Pawlik, K, Lipkowski, AW, Benyhe, S, Makulska-Nowak, H, Ballet, S & Bujalska-Zadrozny, M 2016, 'Biological evaluation and molecular docking studies of AA3052, a compound containing a μ-selective opioid peptide agonist DALDA and D-Phe-Phe-D-Phe-Leu-Leu-NH2, a substance P analogue', European Journal of Pharmaceutical Sciences, vol. 93, pp. 11-20. https://doi.org/10.1016/j.ejps.2016.07.009
Kowalczyk, Agnieszka ; Kleczkowska, Patrycja ; Rękawek, Monika ; Kulik, Kamila ; Lesniak, Anna ; Erdei, A. ; Borics, Attila ; Martin, Charlotte ; Pawlik, Karolina ; Lipkowski, Andrzej W. ; Benyhe, S. ; Makulska-Nowak, Helena ; Ballet, Steven ; Bujalska-Zadrozny, Magdalena. / Biological evaluation and molecular docking studies of AA3052, a compound containing a μ-selective opioid peptide agonist DALDA and D-Phe-Phe-D-Phe-Leu-Leu-NH2, a substance P analogue. In: European Journal of Pharmaceutical Sciences. 2016 ; Vol. 93. pp. 11-20.
@article{5491453753dc45dc836895d3fee4c2e2,
title = "Biological evaluation and molecular docking studies of AA3052, a compound containing a μ-selective opioid peptide agonist DALDA and D-Phe-Phe-D-Phe-Leu-Leu-NH2, a substance P analogue",
abstract = "The design of novel drugs for pain relief with improved analgesic properties and diminished side effect induction profile still remains a challenging pursuit. Tolerance is one of the most burdensome phenomena that may hamper ongoing opioid therapy, especially in chronic pain patients. Therefore, a promising strategy of hybridizing two pharmacophores that target distinct binding sites involved in pain modulation and transmission was established. Previous studies have led to the development of opioid agonist/NK1 agonist hybrids that produce sufficient analgesia and also suppress opioid-induced tolerance development. In our present investigation we assessed the antinociceptive potency of a new AA3052 chimera comprised of a potent MOR selective dermorphin derivative (DALDA) and an NK1 agonist, a stabilized substance P analogue. We have shown that AA3052 significantly prolonged responses to both mechanical and noxious thermal stimuli in rats after intracerebroventricular administration. Additionally, AA3052 did not trigger the development of tolerance in a 6-day daily injection paradigm nor did it produce any sedative effects, as assessed in the rotarod performance test. However, the antinociceptive effect of AA3052 was independent of opioid receptor stimulation by the DALDA pharmacophore as shown in the agonist-stimulated G-protein assay. Altogether the current results confirm the antinociceptive effectiveness of a novel opioid/SP hybrid agonist, AA3052, and more importantly its ability to inhibit the development of tolerance.",
keywords = "Analgesia, Anticancer activity, DALDA, Hybrid peptide, Substance P, Tolerance",
author = "Agnieszka Kowalczyk and Patrycja Kleczkowska and Monika Rękawek and Kamila Kulik and Anna Lesniak and A. Erdei and Attila Borics and Charlotte Martin and Karolina Pawlik and Lipkowski, {Andrzej W.} and S. Benyhe and Helena Makulska-Nowak and Steven Ballet and Magdalena Bujalska-Zadrozny",
year = "2016",
month = "10",
day = "10",
doi = "10.1016/j.ejps.2016.07.009",
language = "English",
volume = "93",
pages = "11--20",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - Biological evaluation and molecular docking studies of AA3052, a compound containing a μ-selective opioid peptide agonist DALDA and D-Phe-Phe-D-Phe-Leu-Leu-NH2, a substance P analogue

AU - Kowalczyk, Agnieszka

AU - Kleczkowska, Patrycja

AU - Rękawek, Monika

AU - Kulik, Kamila

AU - Lesniak, Anna

AU - Erdei, A.

AU - Borics, Attila

AU - Martin, Charlotte

AU - Pawlik, Karolina

AU - Lipkowski, Andrzej W.

AU - Benyhe, S.

AU - Makulska-Nowak, Helena

AU - Ballet, Steven

AU - Bujalska-Zadrozny, Magdalena

PY - 2016/10/10

Y1 - 2016/10/10

N2 - The design of novel drugs for pain relief with improved analgesic properties and diminished side effect induction profile still remains a challenging pursuit. Tolerance is one of the most burdensome phenomena that may hamper ongoing opioid therapy, especially in chronic pain patients. Therefore, a promising strategy of hybridizing two pharmacophores that target distinct binding sites involved in pain modulation and transmission was established. Previous studies have led to the development of opioid agonist/NK1 agonist hybrids that produce sufficient analgesia and also suppress opioid-induced tolerance development. In our present investigation we assessed the antinociceptive potency of a new AA3052 chimera comprised of a potent MOR selective dermorphin derivative (DALDA) and an NK1 agonist, a stabilized substance P analogue. We have shown that AA3052 significantly prolonged responses to both mechanical and noxious thermal stimuli in rats after intracerebroventricular administration. Additionally, AA3052 did not trigger the development of tolerance in a 6-day daily injection paradigm nor did it produce any sedative effects, as assessed in the rotarod performance test. However, the antinociceptive effect of AA3052 was independent of opioid receptor stimulation by the DALDA pharmacophore as shown in the agonist-stimulated G-protein assay. Altogether the current results confirm the antinociceptive effectiveness of a novel opioid/SP hybrid agonist, AA3052, and more importantly its ability to inhibit the development of tolerance.

AB - The design of novel drugs for pain relief with improved analgesic properties and diminished side effect induction profile still remains a challenging pursuit. Tolerance is one of the most burdensome phenomena that may hamper ongoing opioid therapy, especially in chronic pain patients. Therefore, a promising strategy of hybridizing two pharmacophores that target distinct binding sites involved in pain modulation and transmission was established. Previous studies have led to the development of opioid agonist/NK1 agonist hybrids that produce sufficient analgesia and also suppress opioid-induced tolerance development. In our present investigation we assessed the antinociceptive potency of a new AA3052 chimera comprised of a potent MOR selective dermorphin derivative (DALDA) and an NK1 agonist, a stabilized substance P analogue. We have shown that AA3052 significantly prolonged responses to both mechanical and noxious thermal stimuli in rats after intracerebroventricular administration. Additionally, AA3052 did not trigger the development of tolerance in a 6-day daily injection paradigm nor did it produce any sedative effects, as assessed in the rotarod performance test. However, the antinociceptive effect of AA3052 was independent of opioid receptor stimulation by the DALDA pharmacophore as shown in the agonist-stimulated G-protein assay. Altogether the current results confirm the antinociceptive effectiveness of a novel opioid/SP hybrid agonist, AA3052, and more importantly its ability to inhibit the development of tolerance.

KW - Analgesia

KW - Anticancer activity

KW - DALDA

KW - Hybrid peptide

KW - Substance P

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=84978975991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978975991&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2016.07.009

DO - 10.1016/j.ejps.2016.07.009

M3 - Article

VL - 93

SP - 11

EP - 20

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -